Cargando…

来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342280/
https://www.ncbi.nlm.nih.gov/pubmed/28810337
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.07.018
_version_ 1783555430153191424
collection PubMed
description
format Online
Article
Text
id pubmed-7342280
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73422802020-07-16 来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2017-07 /pmc/articles/PMC7342280/ /pubmed/28810337 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.07.018 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察
title 来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察
title_full 来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察
title_fullStr 来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察
title_full_unstemmed 来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察
title_short 来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察
title_sort 来那度胺联合利妥昔单抗治疗13例老年或复发/难治性b细胞非霍奇金淋巴瘤患者的疗效观察
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342280/
https://www.ncbi.nlm.nih.gov/pubmed/28810337
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.07.018
work_keys_str_mv AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá
AT láinàdùànliánhélìtuǒxīdānkàngzhìliáo13lìlǎoniánhuòfùfānánzhìxìngbxìbāofēihuòqíjīnlínbāliúhuànzhědeliáoxiàoguānchá